共 40 条
- [31] Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on I 7 years of follow-up from CheckMate 025 trial.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41George, SabyLarkin, JamesChepynoga, KaterynaSharpe, DanielDe, TuliDyer, MatthewEjzykowicz, FlaviaMay, JessicaKurt, Murat
- [32] A Study of Relationship of Atheroembolic Risk Factors with Postoperative Recovery in Renal Function after Partial Nephrectomy in Patients Staged T1-2 Renal Cell Carcinoma during Median 4-Year Follow-up[J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 288 - 296Kim, Sung HanKang, Kyung MinYu, AmiLee, Jung HoonNam, Byung HoLee, Eun Sik
- [34] Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial Editorial Comment[J]. JOURNAL OF UROLOGY, 2023, 209 (03): : 631 - 632Powles, T.Tomczak, P.Park, S. H.Venugopal, B.Ferguson, T.Symeonides, S. N.Hajek, J.Gurney, H.Chang, Y. -H.Lee, J. L.Sarwar, N.Thiery-Vuillemin, A.Gross-Goupil, M.Mahave, M.Haas, N. B.Sawrycki, P.Burgents, J. E.Xu, L.Imai, K.Quinn, D. I.Choueiri, T. K.
- [35] Re: Long-Term Results of Maintenance Treatment of Mitomycin C or Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy of Patients with Carcinoma In Situ of the Bladder: A Subgroup Analysis of the Prospective Finnbladder 2 Study with a 17-Year Follow-up Editorial Comment[J]. JOURNAL OF UROLOGY, 2013, 190 (06): : 2019 - 2019Wood, David P.
- [36] FIFTEEN YEARS AFTER TREATMENT WITH ONE ADJUVANT CYCLE OF ETOPOSIDE, BLEOMYCIN AND CISPLATIN CHEMOTHERAPY OUTCOMES IN PATIENTS WITH HIGH RISK NONSEMINOMATOUS GERM CELL TUMORS CLINICAL STAGE I. EXTENDED FOLLOW UP OF A PROSPECTIVE SINGLE ARM CLINICAL TRIAL COHORT[J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E117 - E118Faune, Alvaro VidalThalmann, George N.Fey, MartinStuder, Urs E.
- [37] Re: Features Associated with Recurrence beyond 5 Years after Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE Score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project) Editorial Comment[J]. JOURNAL OF UROLOGY, 2014, 191 (04): : 949 - 949Laguna, M. Pilar
- [38] Re: Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE Score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project) Editorial Comment[J]. JOURNAL OF UROLOGY, 2013, 189 (01): : 67 - 68Taneja, Samir S.
- [39] Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1212 - S1212Escudier, B.Motzer, R. J.Dyer, M.May, J. R.Ejzykowicz, F.Kurt, M.Lee, C-W.Wang, P.Testa, E.Sharpe, D. J.George, S.Tannir, N.
- [40] Safety, durable clinical benefit, and remission resulting from nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC); long-term patient follow-up[J]. BJU INTERNATIONAL, 2013, 112 : 9 - 10Drake, C. G.Mcdermott, D. F.Sznol, M.Choueiri, T. K.Kluger, H. M.Powderly, J. D.Smith, D. C.Sankar, V.Gutierrez, A. A.Wigginton, J. M.Gupta, A.Atkins, M. B.